<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">CRH-Positive Hippocampal Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>CRH-Positive Hippocampal Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Corticotropin-releasing hormone (CRH)-positive hippocampal neurons represent a specialized population of peptidergic neurons that play pivotal roles in stress responsivity, synaptic plasticity, learning, and memory. CRH, also known as corticotropin-releasing factor (CRF), is a 41-amino acid neuropeptide synthesized primarily in the paraventricular nucleus (PVN) of the hypothalamus, but also in discrete populations within the hippocampus itself.[@crh_hippocampus_2023] These hippocampal CRH neurons form an intrinsic stress-responsive system that modulates neural circuit function and contributes to both normal cognitive processes and neurodegenerative pathology.[@crh_synaptic_plasticity_2022]
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">CRH-Positive Hippocampal Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>CRH-Positive Hippocampal Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Corticotropin-releasing hormone (CRH)-positive hippocampal neurons represent a specialized population of peptidergic neurons that play pivotal roles in stress responsivity, synaptic plasticity, learning, and memory. CRH, also known as corticotropin-releasing factor (CRF), is a 41-amino acid neuropeptide synthesized primarily in the paraventricular nucleus (PVN) of the hypothalamus, but also in discrete populations within the hippocampus itself.[@crh_hippocampus_2023] These hippocampal CRH neurons form an intrinsic stress-responsive system that modulates neural circuit function and contributes to both normal cognitive processes and neurodegenerative pathology.[@crh_synaptic_plasticity_2022]
The hippocampus, a seahorse-shaped structure in the medial temporal lobe critical for episodic memory formation and spatial navigation, contains CRH-expressing interneurons that influence hippocampal circuitry through volume transmission and synaptic signaling.[@stress_memory_2022] These neurons represent approximately 1-2% of the total hippocampal neuronal population and are predominantly located in the stratum radiatum and stratum lacunosum-moleculare of the CA1 and CA3 regions, with additional populations in the dentate gyrus hilus.
CRH exerts its effects through two main receptor subtypes, CRHR1 and CRHR2, which are G-protein coupled receptors expressed throughout the hippocampal formation. The activation of these receptors triggers downstream signaling cascades involving adenylate cyclase, protein kinase A, and various transcription factors, ultimately modulating neuronal excitability, synaptic plasticity, and gene expression. This receptor system makes hippocampal CRH neurons particularly sensitive to both endogenous stress signals and exogenous stressors.
The CRH precursor peptide is encoded by the CRH gene located on chromosome 8q13. This 191-amino acid pre-pro-CRH molecule undergoes proteolytic processing in the secretory pathway to generate the mature 41-amino acid CRH peptide. The processing involves convertase enzymes that cleave at basic residues, yielding the active peptide with the sequence: SIQPSVGKDP KLLDLDAPRS MDDALLLQAF DQGLAEVHTP EMELFQGKRS EEPKSARKTP SFTSLNLGPQ ESTLEVLGTR SEQDLGLEEK LEAQIHEALK DTLNEREVEI RVRVLNPDTD SAAA.
CRH belongs to a family of related peptides that includes urocortin I, urocortin II (stresscopin), and urocortin III (stresscopin-related peptide). These paralogs bind with varying affinities to CRHR1 and CRHR2 receptors, with urocortins showing higher affinity for CRHR2. The differential expression and binding properties of these peptides allow for nuanced modulation of the stress response system.
The CRH peptide is stored in dense-core vesicles and released via calcium-dependent exocytosis in response to neural inputs, particularly from the amygdala and paraventricular nucleus. The release dynamics differ between phasic and tonic firing modes, with phasic bursts producing transient high concentrations of CRH in the extracellular space.
CRHR1 and CRHR2 are seven-transmembrane domain G-protein coupled receptors that couple primarily to Gs proteins, activating adenylate cyclase and increasing intracellular cAMP. However, they can also couple to Gq proteins, activating phospholipase C and generating inositol trisphosphate (IP3) and diacylglycerol (DAG).
CRHR1 is the predominant receptor in the hippocampus, with highest expression in CA1 pyramidal neurons and dentate granule cells. CRHR1 activation produces:
CRH-positive hippocampal neurons can be identified by:
CRH-expressing neurons in the hippocampus exhibit a characteristic distribution:
CA1 Region: CRH-positive interneurons are concentrated in the stratum radiatum and stratum lacunosum-moleculare. These neurons project to CA1 pyramidal neuron dendrites and modulate synaptic inputs from Schaffer collateral and entorhinal cortical afferents. The CA1 CRH population is particularly sensitive to glucocorticoid modulation.
CA3 Region: CRH neurons in CA3 are found throughout the pyramidal cell layer and stratum lucidum. These neurons receive input from dentate granule cells via mossy fibers and project back to CA3 pyramidal neurons, forming recurrent excitatory circuits. CRH in this region strongly modulates memory consolidation.
Dentate Gyrus: CRH-positive cells are located primarily in the hilus ( polymorphic layer), where they regulate dentate granule cell excitability and modulate flow of information through the trisynaptic circuit. These hilar CRH neurons are sometimes called "hilar peptide interneurons."
CRH hippocampal neurons receive synaptic input from:
CRH hippocampal neurons constitute an intrinsic hippocampal stress response system. When stress activates the hypothalamic-pituitary-adrenal (HPA) axis, glucocorticoids cross the blood-brain barrier and bind to glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) in hippocampal CRH neurons. This glucocorticoid-CRH interaction produces several effects:
CRH modulates both long-term potentiation (LTP) and long-term depression (LTD) in hippocampal synapses:
LTP Enhancement: CRH facilitates LTP induction at Schaffer collateral-CA1 synapses through CRHR1-mediated enhancement of NMDA receptor function. This effect involves:
The CRH system plays a complex, bidirectional role in memory:
Hippocampal CRH neurons contribute to anxiety-related behaviors through projections to the amygdala and hypothalamus. CRHR1 activation in the ventral hippocampus promotes anxiety-like behavior, while CRHR2 activation generally produces anxiolytic effects.
CRH influences adult hippocampal neurogenesis in the dentate gyrus:
Alzheimer's disease (AD) involves significant alterations in the hippocampal CRH system:
CRH Expression Changes: Post-mortem studies of AD hippocampus reveal:
Glucocorticoid-CRH Interaction: AD is associated with HPA axis hyperactivity and elevated cortisol levels. Chronic glucocorticoid exposure:
Synaptic loss is the strongest correlate of cognitive decline in AD. CRH contributes to synaptic dysfunction through:
CRHR1 Antagonists: Selective CRHR1 antagonists are being investigated for AD:
Lifestyle Interventions: Stress reduction through:
The CRH system is altered in Parkinson's disease:
CRH and the hippocampus have bidirectional relationships in epilepsy:
Research on CRH hippocampal neurons employs:
CRHR1 Antagonists:
CRHR2 Agonists:
CRH Peptide Analogues:
CRH-positive hippocampal neurons represent a critical intersection between stress biology and hippocampal function. These peptidergic interneurons modulate synaptic plasticity, memory consolidation, and anxiety-like behaviors through CRHR1 and CRHR2 receptor signaling. In Alzheimer's disease, the CRH system undergoes significant dysregulation, with altered peptide levels, receptor expression, and downstream signaling. This dysfunction contributes to synaptic loss, impaired plasticity, and cognitive decline through multiple mechanisms involving glucocorticoid interactions, amyloid pathology, and tau pathology. Understanding the CRH system's role in neurodegeneration offers therapeutic opportunities through CRHR1 antagonists, stress reduction, and restoration of CRH homeostasis.